Arovella Therapeutics Limited
ALA
Rank in Stocks
#23322
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated... Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Share Price
$0.03530169
Last synced: 2026-11-10
Market Cap
$42.67M
Change (1 day)
2.00%
Change (1 year)
-39.94%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Arovella Therapeutics Limited (ALA)
Category
Healthcare
EPS for Arovella Therapeutics Limited (ALA)
EPS as of June 2026 TTM: $0.00
According to Arovella Therapeutics Limited's latest financial reports, its current EPS (TTM) is $0.00. At the end of 2025 the company had an EPS of 0.00, an increase over its 2024 EPS of $-0.01.
EPS history for Arovella Therapeutics Limited from 2001 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -27.42% |
| 2025 | 0.00 | -27.42% |
| 2024 | $-0.01 | -34.74% |
| 2023 | $-0.01 | -12.04% |
| 2022 | $-0.01 | -6.09% |
| 2021 | $-0.01 | -71.81% |
| 2020 | $-0.04 | -13.38% |
| 2019 | $-0.05 | -22.79% |
| 2018 | $-0.06 | 301.32% |
| 2017 | $-0.02 | -58.36% |
| 2016 | $-0.04 | -22.34% |
| 2015 | $-0.05 | 10.07% |
| 2014 | $-0.04 | -7.17% |
| 2013 | $-0.05 | -67.85% |
| 2012 | $-0.14 | -25.85% |
| 2011 | $-0.19 | -8.83% |
| 2010 | $-0.21 | -6.58% |
| 2009 | $-0.23 | -72.85% |
| 2008 | $-0.83 | 391.52% |
| 2007 | $-0.17 | 565.88% |
| 2006 | $-0.03 | -87.11% |
| 2005 | $-0.20 | 103.50% |
| 2004 | $-0.10 | -27.52% |
| 2003 | $-0.13 | 48.83% |
| 2002 | $-0.09 | 1,265.15% |
| 2001 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 22,720.51% |
US
|
|
| $15.66 | -401,638.46% |
US
|
|
| $-7.07 | 181,182.05% |
US
|
|
| $-5.29 | 135,541.03% |
AU
|
|
| $12.73 | -326,566.67% |
BE
|
Questions about Arovella Therapeutics Limited's earnings per share (EPS)
What is Arovella Therapeutics Limited's earnings per share (EPS)?
Arovella Therapeutics Limited's earnings per share (EPS) over the last twelve months is $0.00, as of Jun 2026.
What was Arovella Therapeutics Limited's earnings per share (EPS) in 2025?
In 2025, Arovella Therapeutics Limited's earnings per share (EPS) was 0.00, compared with $-0.01 in 2024.
How has Arovella Therapeutics Limited's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Arovella Therapeutics Limited's earnings per share (EPS) was highest in 2025 (0.00) and lowest in 2020 ($-0.04).
How does Arovella Therapeutics Limited's earnings per share (EPS) compare with similar companies?
Arovella Therapeutics Limited's earnings per share (EPS) ($0.00) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.